The FDA granted accelerated approval to dordaviprone (Modeyso), developed by Jazz Pharmaceuticals following its acquisition of Chimerix, as the first systemic therapy for recurrent H3 K27M-mutant diffuse midline glioma (DMG), a rare and aggressive pediatric brain cancer. The oral imipridone-class drug targets this high-need disease characterized by poor prognosis. The approval positions Jazz for commercial launch and represents a significant advance in treatment options for this hard-to-treat glioma subtype.